News
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
16h
Everyday Health on MSNZebound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...
1h
MarketBeat on MSNIs It Time to Buy the Dip in Novo Nordisk Stock?CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...
18hon MSN
Gov. Josh Shapiro warned Wednesday that the Medicaid cuts Congress is considering would mean billions of dollars in lost federal aid to ...
Ozempic side effects are a hot topic but don’t panic – our experts are here to help. Here’s what to expect and how to ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results